NASDAQ:AXGNAxoGen Stock Price, Forecast & News

AxoGen's stock was trading at $10.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXGN shares have decreased by 10.0% and is now trading at $9.63. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AxoGen.

AxoGen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for AxoGen.

AxoGen, Inc (NASDAQ:AXGN) released its earnings results on Wednesday, May, 6th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.04. The medical equipment provider had revenue of $24.26 million for the quarter, compared to analyst estimates of $24.30 million. AxoGen had a negative net margin of 25.84% and a negative return on equity of 20.04%. View AxoGen's earnings history.

AxoGen issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $24.3-24.3 million, compared to the consensus revenue estimate of $27.06 million.

5 Wall Street analysts have issued twelve-month price objectives for AxoGen's shares. Their forecasts range from $12.00 to $28.00. On average, they anticipate AxoGen's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 112.9% from the stock's current price. View analysts' price targets for AxoGen.

Headlines about AXGN stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AxoGen earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAxoGen.

AxoGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,740,000 shares, an increase of 24.3% from the April 30th total of 1,400,000 shares. Based on an average trading volume of 559,600 shares, the short-interest ratio is currently 3.1 days. Currently, 4.8% of the shares of the stock are short sold. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), BioLife Solutions (BLFS), TransMedics Group (TMDX), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), BioSig Technologies (BSGM), Cutera (CUTR), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), Fc Global Realty (FCRE) and electroCore (ECOR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Corbus Pharmaceuticals (CRBP), Xilinx (XLNX), Bank of America (BAC), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO) and AMC Entertainment (AMC).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (15.92%), BlackRock Inc. (7.06%), Baillie Gifford & Co. (2.62%), William Blair Investment Management LLC (2.61%), Janus Henderson Group PLC (2.47%) and State Street Corp (2.39%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan and Quentin S Blackford. View institutional ownership trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, State Street Corp, Bank of New York Mellon Corp, Soleus Capital Management L.P., Morgan Stanley, Spark Investment Management LLC, Parametric Portfolio Associates LLC, and Victory Capital Management Inc.. View insider buying and selling activity for AxoGen.

AXGN stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, JPMorgan Chase & Co., William Blair Investment Management LLC, Deutsche Bank AG, Peregrine Capital Management LLC, Geode Capital Management LLC, and Squarepoint Ops LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford. View insider buying and selling activity for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $9.63.

AxoGen has a market capitalization of $382.89 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The official website for AxoGen is www.axogeninc.com.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]